Alzheimer's Disease

A Placebo-Controlled, Double-Blind, Parallel Group, 24 Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer's Disease

 Inclusion/Exclusion Criteria:

  • Male or female subjects between 50 and 85 years of age, inclusive

  • MCI due to AD or Mild AD

  • Must have an identified study partner (defined as a person able to support the subject for the duration of the study and who spends at least 8 hours per week with the subject).

Memory Related Studies
Alzheimer's Disease 

This Phase 3, 36-month study (41 office visits) assesses the safety and efficacy of gantenerumab in patients with early, prodromal to mild Alzheimer's disease. 

Inclusion/Exclusion Criteria:

  • Males or Females 50-90 years old at screening.

  • Evidence of AD pathological process as confirmed by amyloid PET scan or CSF Tau.

  • Demonstrate abnormal memory functions during testing at screening.

  • Has an available study partner (a person who has frequent and sufficient contact with the patient).

  • Click one of the PDF files to learn more

Women's Studies
Uterine Fibroids

This Phase 3, 85-week study (13 office visits) is to demonstrate the superior efficacy versus placebo of a new medication alone and in combination with add-back therapy for the reduction of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

Inclusion/Exclusion Criteria:

  • Must be a premenopausal woman aged 18 years or above

  • Has abnormal heavy menstrual bleeding in a majority of menstrual periods over the last 6 months & has menstrual cycles ≥ 21 days and ≤ 40 days

  • Must be willing to use and collect sanitary protection (pads or tampons) provided by the Sponsor.

  • Must be willing to use non hormonal method of contraception 

Uterine Fibroids 

This Phase 3, 45-week study (8

 office visits) is to evaluate whether an investigational medication impacts heavy menstrual bleeding and other fibroid-related symptoms by blocking the effect of progesterone.

Inclusion/Exclusion Criteria:

  • Must be a premenopausal woman aged 18 years or above

  • Has abnormal heavy menstrual bleeding and/or pelvic pain.

  • Must be willing to use and collect sanitary protection (pads or tampons) provided by the Sponsor.

  • Must be willing to use non hormonal method of contraception 

Hot Flashes

There are two new hot flash studies offered. Both are Phase 3 studies comparing a medication for moderate to severe hot flashes associated with menopause against a placebo. 

Inclusion/Exclusion Criteria:

  • Female between the ages of 40 to 65 years old.

  • Must be seeking treatment for Hot Flashes associated with menopause

  • Must be willing to undergo an endometrial biopsy

  • Must be in good general health 

Hematological Studies 
Sickle Cell Disease

This Phase 2, 15 week study (8 office visits) tests the safety and effectiveness of the investigational drug, how it works compared to a placebo, how it affects your quality of life, how it changes your body's protein signals, and observes the amount of the investigational drug in your blood over time. 

Inclusion/Exclusion Criteria:

  • Must be 16 to 70 years old.

  • Must be diagnosed with Sickle Cell Disease.

  • Have had between 1-10 sickle cell related pain crises in the past 12 months

  • Please follow this link to learn more about the study 

  • https://www.strongscd.com

The Clinical Trial Center LLC

815 Greenwood Avenue

 Jenkintown, PA 19046

Give Us A Call At
(215) 884-1700

OUR HOURS

Monday -  Friday       8:30 am - 5:00 pm
Saturday & Sunday             Closed

Our doctor is on call 24/7 to answer any questions, comments, or concerns

  • w-facebook